42 results about "In vitro stimulation" patented technology

The invention discloses an in-vitro test stimulator, and belongs to the technical field of implanted medical instruments. The in-vitro test stimulator is mainly used for nervous electric stimulation therapy test. The double-channel pulse output in-vitro test stimulator with a user interface can output accurate parameter adjustable electrical stimulation pulse, and is used for treatment test or short-term electric stimulation therapy experience of patients in implanted nerve stimulator operation. The test stimulator is characterized in that the test stimulator adopts integrated structural design, and mainly comprises a shell, a toggle switch, a film key, a display screen, a battery, a printed circuit board and the like. The test stimulator is small and simple; through the key and the switch, pulse parameters and test electrode load impedance can be adjusted and the polarity of an electrode contact can be set, so the test stimulator is intuitive and convenient to operate; and through the design of self-locking function and error operation prevention, error operation of the patients in use can be effectively prevented, and the test stimulator is safe and reliable. The test stimulator can be widely applied to test assessment and experience of electric stimulation therapy.

The invention relates to the field of immune medicine, in particular to a rhamnose lactobacillus Pr2 peptide and a coding gene, a separation method and application thereof. The rhamnose lactobacillus Pr2 peptide has an amino acid sequence shown as SEQ No.1. The rhamnose lactobacillus sourced Pr2 peptide has the capability of producing Tregs through in-vitro stimulus. In addition, the Tregs can produce antigenic specificity Tregs when being exposed under Pr2 and antigen. The antigenic specificity Tregs can be activated when being exposed under specificity antigen. The activated antigenic specificity Tregs can release functional molecules such as IL-10, TGF- beta and FasL. The adoptive transfer of the antigenic specificity Tregs to a sensitized mouse or the giving of the Pr2 and specificityantigen to the sensitized mouse can obviously inhibit the antigenic specificity Th2 reaction and anaphylactic reaction in the body of the mouse. Therefore, the method has the potential application value in the treatment of food allergy diseases.

The invention provides compositions and methods for promoting stem cell and / or progenitor cell proliferation and / or differentiation. The provided compositions may be useful in treating a disease or condition that is related to mucosal barrier function, e.g., wound healing, treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or condition related to the aging of skin), treatinga lung disorders (e.g., asthma), a condition related to improving mucosal barrier function, and / or treating injury to GI mucosa in a subject in need thereof. The invention also provides methods for promoting the proliferation and / or differentiation of stem cells and / or the progenitor cells in a subject in need of such treatment by administering a composition. The ability to stimulate the proliferation and / or differentiation of stem cells and / or the progenitor cells in vivo, ex vivo and / or in vitro provides tremendous benefit. The compositions can be used to increase stem cell populations in vivo, ex vivo and / or in vitro. Stem cell transplantation provides treatments and / or cures of many disease states, degeneration and / or injury.

The invention belongs to the field of medical biology engineering, and particularly relates to a method for effectively multiplying gamma delta T cells by stimulating peripheral blood in vitro and application of the method. The method comprises the step of using feeder cells, an OKT3 (ornithine ketoacid transaminase) antibody, interleukin-2 and zoledronic acid. The feeder cells are formed by specifically inserting CD64, CD86 and CD137L genes in a target site of a genome of the feeder cells. After the zoledronic acid and the nterleukin-2 are used for increasing the proportion of the gamma delta T cells of the peripheral blood, protein products of genes, the OKT3 antibody and the interleukin-2 act in a combined manner, and the gamma delta T cells can be stimulated so that a large amount of gamma delta T cells can be multiplied. The multiplied gamma delta T cells can be used for killing tumor cells which are pretreated by the zoledronic acid, or the tumor cells can be directly killed by modifying and expressing chimeric antigen receptors (CAR) via a genetic engineering means. The gamma delta T cells which are obtained by the method have complete anti-tumor cytotoxicity, and can kill solid tumor cells and non-solid tumor cells.

A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least 5 million cells that have a density of less than 1.072 g / ml, and at least 1% of which are CD34+CD45− / dim, to differentiate into a progenitor / precursor cell population (PCP). A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least ten thousand cells that have a density of less than 1.072 g / ml to differentiate into a progenitor / precursor cell population (PCP). A method is provided, including separating lower density cells from higher density cells, the lower density cells defining an initiating cell population (ICP), and in vitro stimulating the ICP to differentiate into a progenitor / precursor cell population (PCP). Other embodiments are also described.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor- associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex(MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention relates to a medical suture friction testing apparatus. The apparatus comprises an assembly for testing the friction performance of a medical suture when the medical suture penetrates tissues, and an assembly for testing the friction performance between medical sutures. The assembly for testing the friction performance of a medical suture penetrating tissues stimulates the friction performance between the medical suture and all tissues when the medical suture penetrates human tissues, and the assembly for testing the friction performance between medical sutures stimulates the friction assembly between the medical sutures in the knotting process of the medical suture. The two assemblies can be arranged in a multifunctional fiber strength and elongation tester to replace a lower clamping head of the tester in order to carry out relevant friction performance test. The invention also discloses a corresponding medical suture friction testing method. The friction testing apparatus has the advantages of simple structure, convenient operation, and objective and real result. The apparatus and the method fill up a blank in the quantitative characterization of present in-vitro stimulation of the friction performance of the medical suture, and provide scientific bases for the improvement of the structure of the medical suture.

Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood.